School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
BMC Cancer. 2023 Jun 27;23(1):595. doi: 10.1186/s12885-023-11075-y.
Although the incidence of late-onset colorectal cancer (LOCRC) has decreased, the incidence of early-onset colorectal cancer (EOCRC) is still rising dramatically. Heterogeneity in the genomic, biological, and clinicopathological characteristics between EOCRC and LOCRC has been revealed. Therefore, the previous prognostic models based on the total CRC patient population might not be suitable for EOCRC patients. Here, we constructed a prognostic classifier to enhance the precision of individualized treatment and management of EOCRC patients.
EOCRC expression data were downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. The regulatory pathways were explored by gene set enrichment analysis (GSEA). The prognostic model was developed by univariate Cox-LASSO-multivariate Cox regression analyses of GEO samples. TCGA samples were used to verify the model. The expression and mutation profiles and immune landscape of the high-risk and low-risk cohorts were analyzed and compared. Finally, the expression and prognostic value of the model genes were verified by immunohistochemistry and qRT‒PCR analysis.
The cell cycle was identified as the most significantly enriched oncological signature of EOCRC. Then, a 4-gene prognostic signature comprising MCM2, INHBA, CGREF1, and KLF9 was constructed. The risk score was an independent predictor of overall survival. The area under the curve values of the classifier for 1-, 3-, and 5-year survival were 0.856, 0.893, and 0.826, respectively, in the training set and 0.749, 0.858, and 0.865, respectively, in the validation set. Impaired DNA damage repair capability (p < 0.05) and frequent PIK3CA mutations (p < 0.05) were found in the high-risk cohort. CD8 T cells (p < 0.05), activated memory CD4 T cells (p < 0.01), and activated dendritic cells (p < 0.05) were clustered in the low-risk group. Finally, we verified the expression of MCM2, INHBA, CGREF1, and KLF9. Their prognostic value was closely related to age.
In this study, a robust prognostic classifier for EOCRC was established and validated. The findings may provide a reference for individualized treatment and medical decision-making for patients with EOCRC.
尽管迟发性结直肠癌(LOCRC)的发病率有所下降,但早发性结直肠癌(EOCRC)的发病率仍在急剧上升。EOCRC 和 LOCRC 在基因组、生物学和临床病理特征方面存在异质性。因此,以前基于总 CRC 患者人群的预后模型可能不适用于 EOCRC 患者。在这里,我们构建了一个预后分类器,以提高 EOCRC 患者个体化治疗和管理的精确性。
从基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据库下载 EOCRC 表达数据。通过基因集富集分析(GSEA)探索调控途径。通过 GEO 样本的单变量 Cox-LASSO-多变量 Cox 回归分析,构建预后模型。使用 TCGA 样本验证模型。分析和比较高危和低危队列的表达和突变谱以及免疫景观。最后,通过免疫组化和 qRT-PCR 分析验证模型基因的表达和预后价值。
细胞周期被确定为 EOCRC 最显著富集的肿瘤特征。然后,构建了一个由 MCM2、INHBA、CGREF1 和 KLF9 组成的 4 基因预后标志物。风险评分是总生存期的独立预测因子。在训练集中,该分类器的 1 年、3 年和 5 年生存率的曲线下面积值分别为 0.856、0.893 和 0.826,在验证集中分别为 0.749、0.858 和 0.865。在高危组中发现 DNA 损伤修复能力受损(p<0.05)和频繁的 PIK3CA 突变(p<0.05)。CD8 T 细胞(p<0.05)、活化记忆 CD4 T 细胞(p<0.01)和活化树突状细胞(p<0.05)在低危组中聚集。最后,我们验证了 MCM2、INHBA、CGREF1 和 KLF9 的表达。它们的预后价值与年龄密切相关。
本研究建立并验证了一种用于 EOCRC 的稳健预后分类器。这些发现可能为 EOCRC 患者的个体化治疗和医疗决策提供参考。